title: Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.
abstract: OBJECTIVE
  In multiple sclerosis (MS), contrast-enhancing lesions (CELs) in T1-weighted postcontrast MRI are considered markers of blood-brain barrier breakdown. It remains unknown if re-enhancement can be considered a radiologic indicator of different pathology in CELs. We investigated 1) the incidence of re-enhancing lesions (re-CELs) from chronic lesions; 2) differences in size, magnetization transfer ratio (MTR), and likelihood to appear as acute black holes (aBHs) between new lesions (n-CELs) and re-CELs; and 3) associations between re-CELs and features indicating more advanced disease.
  
  
  METHODS
  In this retrospective natural history study, we examined 264 monthly MRI scans performed at month 1 (M1), month 2 (M2), and month 3 (M3) for 88 patients with MS. CELs were defined as n-CELs if not present in the M1 T2W MRI and re-CELs if present in the M1 T2W MRI.
  
  
  RESULTS
  A total of 311 (82.7%) n-CELs and 65 (17.3%) re-CELs were identified. Of the 88 patients, 54 presented only n-CELs, 8 presented only re-CELs, and 26 presented both CEL types. Patients with both lesion types presented more CELs than those presenting only one type (p = 0.01). Re-CELs were larger (z = 2.72, p = 0.007) and had lower MTR (z = -2.80, p = 0.005) than n-CELs but the estimated proportion of aBHs from n-CELs was similar (z = -0.09, p = 0.1) from the proportion of aBHs from re-CELs.
  
  
  CONCLUSIONS
  Nearly 20% of CELs represent the reoccurrence of enhancement in chronic plaques. Re-CELs represent larger areas of inflammation, not necessarily associated with larger areas of edema.
authors.affiliation: Neuroimmunology Branch (NIB), NIH, Bethesda, MD, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Campbell
authors.forename: D
authors.initials: D
authors.lastname: Sahm
authors.forename: K
authors.initials: K
authors.lastname: Donohue
authors.forename: J
authors.initials: J
authors.lastname: Jamison
authors.forename: M
authors.initials: M
authors.lastname: Davis
authors.forename: C
authors.initials: C
authors.lastname: Pellicano
authors.forename: S
authors.initials: S
authors.lastname: Auh
authors.forename: J
authors.initials: J
authors.lastname: Ohayon
authors.forename: J A
authors.initials: JA
authors.lastname: Frank
authors.forename: N
authors.initials: N
authors.lastname: Richert
authors.forename: F
authors.initials: F
authors.lastname: Bagnato
mesh_terms: D000328:Adult; D001812:Blood-Brain Barrier / Q000473:pathology; D001921:Brain / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000473:pathology*; D009413:Nerve Fibers, Myelinated / Q000473:pathology*; D012189:Retrospective Studies